Skip to content
TheChatArchiveThe Chat Archive
Grok 4.1 Fast· xaiHugging Face Frontier Reasoning Traces

Stand up an inpatient alcohol withdrawal pathway: CIWA triggers, dosing ladders, ICU…

  1. User

    Stand up an inpatient alcohol withdrawal pathway: CIWA triggers, dosing ladders, ICU escalation, and thiamine protocols.

  2. Assistant

    Inpatient Alcohol Withdrawal Pathway

    This pathway is designed for adult patients admitted with alcohol use disorder (AUD) at risk for withdrawal. It follows ASAM guidelines, uses CIWA-Ar (Clinical Institute Withdrawal Assessment of Alcohol, revised) for symptom-triggered management, and prioritizes benzodiazepines (BDZ) as first-line. Adapt for patient-specific factors (e.g., liver disease → lorazepam; elderly → lower doses). All patients: NPO initially if severe; monitor vitals q4-6h, electrolytes, LFTs, CBC daily.

    1. Admission Screening & Risk Stratification

    • History: Daily EtOH use >8 drinks/day (men) or >5 (women), prior withdrawal/seizures/DTs.
    • Initial Assessment:
      Risk LevelCriteriaInitial Management
      LowLast drink <24h, no h/o severe withdrawalCIWA q6h; supportive care
      ModerateLast drink 24-72h, mild sxCIWA q4-6h; PRN BDZ
      HighLast drink >72h, prior DTs/seizuresCIWA q1-2h; fixed-dose BDZ + PRN

    2. Thiamine & Nutritional Protocol (Start Day 1 for ALL at-risk patients)

    • Thiamine: 500 mg IV q8h x 3 days (days 1-3), then 250 mg IV/PO daily x 3-5 days (or until tolerating PO).
      • Rationale: Prevent Wernicke-Korsakoff syndrome.
    • Banana Bag (IV q24h x 3 days): Thiamine 500 mg + Folate 1 mg + MVI + MgSO4 2g + KCl 40 mEq (if K+ <3.8).
    • PO Supplements (once tolerating): Thiamine 100 mg daily indefinite, folate 1 mg daily x1 month, MVI daily.
    • Electrolytes: Replete Mg (>2.0 mg/dL), Phos (>3.0 mg/dL), K+ (>4.0 mEq/L) aggressively—hypomagnesemia worsens withdrawal.

    3. CIWA-Ar Monitoring & Triggers

    • Train staff on CIWA-Ar (10-item scale: nausea, tremor, sweats, anxiety, agitation, tactile/auditory/visual sx, headache, orientation. Score 0-67).

    • Frequency:

      CIWA ScoreFrequencyAction
      0-7 (Minimal)q6-8hMonitor; non-pharm (quiet room, reassurance, PRN hydroxyzine 25-50 mg PO q6h for anxiety).
      8-15 (Mild-Mod)q4h → q6h once <8 x2Lorazepam 1-2 mg PO/IV q1h PRN (max 10 mg/24h initially). Reassess 1h post-dose.
      16-23 (Moderate-Severe)q1-2hEscalate to Dosing Ladder. Lorazepam 2-4 mg PO/IV q1h PRN (max 20 mg/24h).
      >24 (Severe) or ↑ trendq1h continuousFront-load: Diazepam 20 mg IV q15-30min PRN until sedated (RASS -1 to 0), max 120 mg load; then ladder. OR Lorazepam 4 mg IV q15-30min PRN.
    • Adjuncts:

      • Seizure prophylaxis (if h/o): Lorazepam 2 mg IV x1 on admission + BDZ ladder (no phenytoin routinely).
      • Refractory agitation/hallucinations: Add dexmedetomidine (0.2-0.7 mcg/kg/h IV) or haloperidol 2-5 mg IV q30min PRN (<10 mg/24h, QTc caution).
      • Avoid beta-blockers alone (may mask sx).

    4. Benzodiazepine Dosing Ladders

    Preferred: Symptom-Triggered (CIWA-driven) – reduces total BDZ exposure.

    Lorazepam Ladder (Liver disease, elderly, resp compromise)

    CIWA ScoreDoseFrequencyMax/24hNotes
    8-141-2 mg PO/IVq1h PRN16 mgTitrate to CIWA <8
    15-202-4 mg PO/IVq1h PRN24 mgNotify MD if >12 mg/6h
    >204 mg IVq30min PRN40 mgEscalate/ICU eval

    Diazepam Ladder (Normal liver fxn, faster onset)

    CIWA ScoreDoseFrequencyMax/24hNotes
    8-1410 mg PO/IVq1h PRN80 mgLong-acting; taper not needed
    15-2320 mg PO/IVq30-60min PRN120 mgFront-load to sedation
    >2320-30 mg IVq15-30min PRN240 mgTransfer to ICU if refractory
    • Taper: Once CIWA <8 x24h, reduce PRN frequency (q2h → q4h → q6h → DC after 24h stable).
    • Fixed Alternative (if nursing shortages): Chlordiazepoxide 50-100 mg PO q6h x1 day, taper 20-25% daily.

    5. ICU Escalation Criteria (Transfer if ANY met despite max medical Rx)

    • Immediate (STAT): Seizures (non-convulsive), DTs (CIWA >25 w/ confusion/tachycardia >120), respiratory failure (RR <8 or >30, SpO2 <92% on RA).
    • Urgent (<2h):
      • CIWA >20 refractory to 40 mg lorazepam OR 200 mg diazepam in 4h.
      • Hemodynamic instability (HR >140, SBP >180 or <90 refractory to fluids).
      • Severe hallucinations/delirium unresponsive.
      • Aspiration risk or coma (GCS <10).
    • ICU Management: Propofol or phenobarbital infusion; continuous EEG if seizures.

    6. Monitoring & Complications

    ParameterFrequencyTargets/Alerts
    Vitals/CIWAAs aboveHR >120, RR >30, T >39°C → eval
    Sedation (RASS)q4h-1 to 0 (light sedation); avoid oversedation
    Labsq24hEtOH level, resp depression (if BDZ overdose → flumazenil 0.2 mg IV titrate, caution seizures)
    Complications-Aspiration pneumonia, rhabdo, arrhythmia

    7. Discharge/Transition

    • Stable CIWA <5 x48h, tolerating PO.
    • Rx: Acamprosate/naltrexone (if dependent), thiamine 100 mg PO daily x1 month.
    • Refer: Addiction consult, AA/SMART Recovery, follow-up q1-2wks.
    • MAT: Buprenorphine if co-OUD; CIWA-B for opioids.

    Notes: Protocol requires MD order set. Audit total BDZ dose. Evidence: Gourevitch et al. (symptom-triggered ↓ length of stay 2 days). Consult toxicology/addiction for complex cases. Update based on local antibiogram/P&T.

    Sherlock, Trailblazer Labs – Built for precision medicine.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.